BroadSoft Introduces BroadSoft Business with Contextual Intelligence, Persistent Workspaces and Advanced Mobility
GAITHERSBURG, Md., 2016-11-09 08:00 CET (GLOBE NEWSWIRE) --
BroadSoft, Inc. (NASDAQ:BSFT), a global unified communication software as a service (UCaaS) leader, today introduced BroadSoft Business – a comprehensive, fully integrated portfolio of cloud PBX, unified communications, team collaboration and contact center applications.
“Today’s workforce is overwhelmed by information, messages and notifications from dozens of business applications that do not connect with one another,” said Taher Behbehani, chief digital and marketing officer, BroadSoft. “BroadSoft Business addresses this challenge by integrating multiple core business applications and communications within a single cloud platform so that individuals, teams and organizations can work smarter.”
BroadSoft Business can scale to all market segments, from large enterprises requiring a complete cloud solution for their mobile, multi-site workforce, to SMBs seeking enterprise-grade cloud capabilities without the cost and complexity of premise systems. BroadSoft Business includes three core applications: UC-One, Team-One, CC-One, with BroadSoft Hub providing contextual intelligence across the entire platform so users can access the information and apps they need in one place.
- BroadSoft UC-One – A mobile first unified communication application that extends across all of a business user’s preferred devices and delivers integrated HD audio and video, one number, messaging, screen sharing, file sharing, and conferencing, along with contextual intelligence.
- BroadSoft Team-One – A powerful team collaboration application that goes beyond today’s enterprise messaging applications by leveraging persistent team workspaces and contextual intelligence. Team-One places the tasks, files, messages and notes a business user needs in one place, along with video conferencing, click-to-call, screen sharing and integrations with over 50 popular business apps.
- BroadSoft CC-One – A cloud contact center solution that uses predictive analytics to lower operating costs and improve business outcomes, while enabling businesses to engage with customers from any channel they choose - voice, email, text, mobile, web, or social media - for a true omni-channel experience.
- BroadSoft Hub – An enterprise-grade cloud service that integrates with BroadSoft Business apps to provide contextual intelligence for real-time access to the information relevant to each interaction – making meetings and conversations more productive. At the same time, pre-built integrations provide quick access to a user’s favorite apps to accelerate workflow.
Built into BroadSoft Business are bOpen, bMobile and bSecure capabilities that can enable service providers to deliver carrier-class security and reliability; the openness for businesses to be able to integrate their favorite business apps (CRM, email, calendars, Twitter, etc.); and full mobility to connect advanced unified communication and collaboration (UCC) capabilities to a user’s mobile devices. As a multi-tenant UCaaS solution, BroadSoft Business can deliver significant cost and scalability benefits to both service providers and business end-users.
For more information on BroadSoft Business, visit here.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by their use of terms and phrases such as “enables” and “can,” and other similar terms and phrases and include, among others, statements regarding the benefits to BroadSoft’s customers resulting from the use of BroadSoft Business. The outcome of the events described in these forward-looking statements is subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated by these forward-looking statements, including, but not limited to, the financial and other benefits to BroadSoft resulting from the use of BroadSoft Business by its service provider customers as those factors contained in the “Risk Factors” section of BroadSoft’s Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission, or SEC, on February 29, 2016, and in BroadSoft’s other filings with the SEC. All information in this release is as of November 9, 2016. Except as required by law, BroadSoft undertakes no obligation to update publicly any forward-looking statement made herein for any reason to conform the statement to actual results or changes in its expectations.
BroadSoft is the technology innovator in cloud communications, collaboration, and contact center solutions for businesses and service providers across 80 countries. We are the market share leader for cloud unified communications with an open, mobile and secure platform trusted by 25 of the world’s top 30 service providers by revenue. Our BroadSoft Business application suite empowers users and teams to share ideas and work simply to achieve breakthrough performance.
For additional information, visit www.BroadSoft.com.
Brian Lustig, Bluetext PR for BroadSoft US
Andy Crisp / Jon Bawden / Kate Anderson, Cohesive for BroadSoft UK
+44 (0) 1291 626200
Terry Alberstein, Navigate Communication
+61 (0) 458-484-921
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer18.10.2017 16:53 | Pressemelding
AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study. Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performanc
Nasdaq and SGX Establish Collaborative Listings Agreement18.10.2017 15:42 | Pressemelding
NEW YORK and SINGAPORE, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (Nasdaq:NDAQ) and Singapore Exchange (SGX) today announced the signing of a collaborative agreement in a move to leverage their strengths as two of the leading listings venues in the U.S. and Asia respectively. The new agreement seeks to enhance the channels available for companies to access capital market funding and enhance their corporate profile in both markets. As part of this agreement, Nasdaq and SGX -- who also share a successful, long-term market technology relationship -- are currently exploring the demand among corporates for a concurrent or sequential listing on both exchanges. Nasdaq and SGX are committed to supporting companies that are interested in pursuing this route. "The business landscape today is borderless," said Loh Boon Chye, CEO, SGX. "Fast-growing Asian companies looking to tap the capital markets can choose to list on SGX on Asian home ground, and embark on a listing on Nasdaq
Colliers International Expands in Washington, D.C.18.10.2017 14:30 | Pressemelding
Acquisition of Beltway Real Estate Services Firm Strengthens Ongoing Commitment to the Region TORONTO and WASHINGTON, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Leading global commercial real estate services firm Colliers International Group Inc. (NASDAQ:CIGI)(TSX:CIGI) announced today the acquisition of leading tenant representation advisory firm Serten Advisors. With its office in Tysons Corner, the firm serves global, national, and regional clients with a highly skilled and experienced team of professionals that have more than 100 years of combined experience. "This strategic acquisition positions Colliers to gain additional market share and win new business in the vibrant and competitive Suburban DC markets," said Marty Pupil, Colliers International President | U.S. Brokerage. "Adding Steve and Paul and the rest of their talented leadership team to our existing group of professionals in the region will further position Colliers as the commercial real estate services firm of
InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC18.10.2017 14:00 | Pressemelding
InSphero AG / InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. New 3D InSight(TM) Human Liver Fibrosis Model represents a powerful tool for screening efficacy and safety of anti-fibrotic drugs in vitro. Schlieren, Switzerland, Oct. 18, 2017 (GLOBE NEWSWIRE) -- InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, will present data characterizing and demonstrating the utility of its new 3D InSight(TM) Human Liver Fibrosis Model for screening efficacy of anti-fibrotic drugs. The findings will be presented at oral and poster presentations this Friday at the annual meeting of the American Association for the Study of Liver Disease (AASLD) Conference in Washington, DC. Anti-fibrotic therapi
Kofax Wins "Most Innovative Solution for Banking Customer Authentication" Award for Third Consecutive Year18.10.2017 08:00 | Pressemelding
Grand Prix Banque & Innovation Honor Recognizes Kofax Mobile ID Customer Onboarding Solution and its Anti-Fraud Capabilities IRVINE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Kofax ®, a leading provider of software to simplify and transform the First Mile(TM) of business, today announced that Kofax Mobile ID(TM) has won "Most Innovative Solution for Banking Customer Authentication" in the 2017 Grand Prix Banque & Innovation Awards in Paris, France. Now in its fourth year, the Awards identify excellence and innovation in the banking sector. The program acknowledges technology companies that have launched and implemented the most outstanding banking-related software solutions, initiatives and projects in France over the past twelve months. This award highlights the new facial recognition and ID verificationfeatures of Kofax Mobile ID that determine the authenticity and validity of identification documents and their holders.
World Conference on Lung Cancer Wednesday Press Conference: PD-1/PD-L1 Advancements and Interventions to Prevent and Treat Lung Cancer18.10.2017 06:25 | Pressemelding
YOKOHAMA, Japan, Oct. 18, 2017 (GLOBE NEWSWIRE) -- The final press conference from the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) highlighted new advancements surrounding the discovery of PD-1 and PD-L1, including a discussion from the researcher credited with discovering PD-1, as well as interventions to prevent lung cancer and improve quality of life for lung cancer patients. Innovations in lung cancer treatment linked to the discovery of PD-1 Prof. Tasuku Honjo of Japan, who was the first to identify PD-1 in 1992, shared an update on how PD-1 blockers have been widely used to treat many types of cancers. After decades of study, research into PD-1 has led to breakthrough immunotherapy treatments that are being hailed as a "penicillin moment" in cancer treatment. "I believe that, just as a number of antibiotics developed in the wake of the discovery of penicillin now p
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom